Abstract
The latest study shows that the expression abnormalities of programmed death 1/programmed death ligand 1 (PD-1/PD-L1) signaling pathway in a variety of solid tumor tissues and cells are related to disease progression and poor prognosis, and directly involve in tumor immune escape, becoming the recent focus. With the further research, PD-1/PD-L1 signaling pathway in blood diseases, for example, in the development of lymphoma, is catching more attention gradually. The signaling pathway not only is associated significantly with malignancy, progression, recurrence of lymphoma and prognosis of patients, but probably becomes a new target for cancer immunotherapy. This paper summarizes the expression and research status of the biological characteristics and mechanism of PD-1/PD-L1 signaling pathway in lymphoma, in order to provide a new way for lymphoma treatment. Key words: Lymphoma; Programmed death 1; Signal transduction
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
